Ketamine is a special kind of anesthetic. The drug was first used as a monoanesthesia in therapeutic therapy inducing analgesia, forgetfulness, unconsciousness, and immobility more than thirty years ago. In a racemic combination, ketamine is often present in equal proportions to the enantiomers S(-) and R(+)-ketamine. From a pharmacological standpoint, ketamine's main target is glutamate, the brain's main excitatory neurotransmitter. It is an adversary that does not compete, operating at the N-methyl-d-aspartate receptor, one of the three glutamate receptors. Because of its short half-life and lack of clinically significant respiratory depression, ketamine has proven to be a successful treatment despite its negative effects. Much is still unknown about the epidemiology of ketamine, specifically concerning the frequency of its and in what settings, and the trends over the years. The review aimed to draw focus on ketamine's significant neurobehavioral activity, mechanism of action, use, misuse, abuse, and adverse consequences.